moksha8 Pharmaceuticals Competitors and Similar CompaniesClear all
moksha8 Pharmaceuticals's competitors and similar companies include Supernus Pharmaceuticals, Calliditas Therapeutics, Autifony Therapeutics and Ethismos Research.
 moksha8 Pharmaceuticals Moksha8 is a pharmaceutical company which provides therapeutics for the treatment of central nervous system and mental health disorders. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. |  Calliditas Therapeutics Calliditas Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments in orphan indications. |  Autifony Therapeutics Autifony Therapeutics is a biotechnology company that develops new drugs to treat serious disorders of the central nervous system. |  Ethismos Research Ethismos Research is a drug discovery company developing therapies to address addiction and depression. | |
Founding Date | Founding Date 2006 | Founding Date 2005 | Founding Date 2004 | Founding Date 2011 | Founding Date N/A |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Berwyn, US HQ Ciudad De México, MX | Locations Rockville, US HQ | Locations Stockholm, SE HQ Archamps, FR Stockholm, SE Stockholm, SE Plan Les Ouates, CH Hoboken, US New York, US | Locations Stevenage, GB HQ Padova, IT | Locations Cambridge, US HQ |
Employees | Employees 3702% decrease | Employees 6527% increase | Employees 2221% increase | Employees 36 | Employees 18 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.9 b | Valuation ($) 1.1 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $661.8m (FY, 2024) | Revenue (est.) kr1.2b (FY, 2023) | Revenue (est.) £22.8m (FY, 2018) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $77.9m (FY, 2024) | Cost of goods kr60.5m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $583.9m (FY, 2024) | Gross profit kr1.2b (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income $73.9m (FY, 2024) | Net income (kr466.2m) (FY, 2023) | Net income £16.2m (FY, 2018) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 125m (over 12 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 12.3m (almost 10 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 224.1m | Total funding raised $ 69.5m | Total funding raised $ 33.2m | Total funding raised $ 24.2m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Supernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View companyCalliditas Therapeutics
HQ
Stockholm, SE
Employees
222↑ 1% increase
Calliditas Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments in orphan indications.
View companyAutifony Therapeutics
HQ
Stevenage, GB
Employees
36
Autifony Therapeutics is a biotechnology company that develops new drugs to treat serious disorders of the central nervous system.
View companyEthismos Research
HQ
Cambridge, US
Employees
18
Ethismos Research is a drug discovery company developing therapies to address addiction and depression.
View company